HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

h as improvement in disease-related symptoms or increased survival.

How DOXIL Works
DOXIL is an advanced form of doxorubicin, a liposomal formulation of doxorubicin, which means that doxorubicin is encapsulated by a fatty bilayer. The liposome is pegylated, which helps protect the drug from the immune system, resulting in the product circulating in the blood for a longer period of time. The longer circulation allows dosing once every four weeks.

Administration
DOXIL is administered intravenously in the doctor's office or clinic. Treatment usually takes from 30 minutes to one hour, though the first treatment may be longer.

  • To manage adverse events such as PPE, stomatitis, or hematologic toxicity, the dose may be delayed or reduced;
  • Pretreatment with or concomitant use of antiemetics should be considered; and
  • Limited clinical experience exists in treating hepatically impaired patients with DOXIL. Based on experience with doxorubicin HCl, it is recommended that DOXIL dosage be reduced if the bilirubin is elevated as follows: Serum bilirubin 1.2 to 3.0 mg/dL give normal dose, >3.0 mg/dL give normal dose.

Efficacy
DOXIL's refractory ovarian cancer indication was based on the results of three Phase II trials involving patients with metastatic ovarian cancer that was resistant to conventional chemotherapy. Most of the patients had been treated with two or more rounds of conventional chemotherapy, but the tumor was still progressing.

In these studies, patients with refractory metastatic ovarian cancer treated with DOXIL had a 13.8% (20/145) (95% CI 8.1% to 19.3%) combined response rate. The median time to response was 18 weeks, median duration of response was 39 weeks, and median time to disease progression was 16 weeks.

Warnings
In clinical trials, the most common side effects reported with DOXIL therapy included reduced red blood cel
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical study reports findings combination therapy with DOXIL

(Date:10/31/2014)... study confirms that endangered musk deer still live in ... Species targeted by poachers: Musk deer scent glands are ... October issue of the journal Oryx , ... years after its last confirmed sighting, a strange deer ... slopes of northeast Afghanistan according to a research team ...
(Date:10/31/2014)... creating green space in cities is good for attracting species, ... built environments, a University of Iowa study has found. , ... area in Iowa, and recorded the abundance of two insects ... plenty of the trees, black cherry and black walnut, they ... case fruit flies that feed on the walnuts and black ...
(Date:10/31/2014)... Thomas Bugnyar and his team have been studying ... the Northern Austrian Alps for years. They observed ... such as grooming and playing. However, they also ... by a third individual. Although in about 50 ... and broke up the two affiliating ravens, intervening ...
Breaking Biology News(10 mins):Strange, fanged deer persists in Afghanistan 2Green spaces don't ensure biodiversity in urban areas 2
(Date:10/31/2014)... October 31, 2014 The report ... Rice), Formulation (Plain, Flavored, Sweetened, Unsweetened), Channel (Supermarket, ... Global Trends & Forecast to 2018," defines and ... analysis and forecast of revenue and volume for ... is projected to reach $14 Billion by 2018 ...
(Date:10/31/2014)... ORLANDO, Fla. , Oct. 31, 2014 /PRNewswire/ ... firm owned by Tavistock Group, celebrated the groundbreaking of ... Nona Medical City. The 92,000-square-foot, ... Central Florida designed specifically ... Located in the heart of the 650-acre Lake ...
(Date:10/30/2014)... , Oct. 30, 2014  Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, today ... financial results on Thursday, November 6, 2014. Following ... a live conference call and webcast at 4:30pm ... provide a business update. The live ...
(Date:10/30/2014)... MA (PRWEB) October 30, 2014 ... and collaboration provider, offers Office 365 end users ... into a complete phone system by adding voice ... 365 (O365) includes Lync Online, a communication tool ... Lync calls. With hosted voice, O365 becomes a ...
Breaking Biology Technology:Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3
Cached News: